← All trials
NCT05671822
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2023
- Primary completion
- Jul 30, 2026
- Completion date
- Jul 30, 2026
- First posted
- Jan 5, 2023
- Last posted
- Apr 7, 2023
- Enrollment
- 156
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.